TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: <0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: <0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: <0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: <0.0720nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.0860nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.0970nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.0990nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.113nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.120nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.131nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.138nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.138nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.149nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.155nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.161nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.176nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.177nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.209nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.212nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.212nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.213nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.218nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.220nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.239nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.246nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.259nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.260nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.268nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.280nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.300nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.309nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.310nMAssay Description:Exon 20-Mutant-EGFR(D770_N771insSVD): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-329]/Phorbol-Phorbol-12-myristate-13-acetate-induced protein 1 [26-43](Homo sapiens (Human))
The Broad Institute
US Patent
The Broad Institute
US Patent
Affinity DataIC50: 0.310nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.322nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.330nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-329]/Phorbol-Phorbol-12-myristate-13-acetate-induced protein 1 [26-43](Homo sapiens (Human))
The Broad Institute
US Patent
The Broad Institute
US Patent
Affinity DataIC50: 0.340nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-329]/Phorbol-Phorbol-12-myristate-13-acetate-induced protein 1 [26-43](Homo sapiens (Human))
The Broad Institute
US Patent
The Broad Institute
US Patent
Affinity DataIC50: 0.340nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.342nMAssay Description:Exon 20-Mutant-EGFR(V769_D770insASV): For the assay 50 nl of a 100-fold concentrated solution of the test compound in DMSO was pipetted into either a...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.370nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.370nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.390nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-329]/Phorbol-Phorbol-12-myristate-13-acetate-induced protein 1 [26-43](Homo sapiens (Human))
The Broad Institute
US Patent
The Broad Institute
US Patent
Affinity DataIC50: 0.400nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.410nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.420nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1(Homo sapiens (Human))
The Broad Institute
US Patent
The Broad Institute
US Patent
Affinity DataIC50: 0.450nMAssay Description:MCL-1 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1....More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.460nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.460nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.480nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.480nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-329]/Phorbol-Phorbol-12-myristate-13-acetate-induced protein 1 [26-43](Homo sapiens (Human))
The Broad Institute
US Patent
The Broad Institute
US Patent
Affinity DataIC50: 0.480nMAssay Description:MCL-1/Noxa BH3 Peptide (MCL-1 Assay): From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay wa...More data for this Ligand-Target Pair